BridgeBio director granted RSUs and stock options

BridgeBio Pharma director Ronald J. Daniels reported equity awards as part of his compensation.

Rhea-AI Filing Summary

BridgeBio Pharma director Ronald J. Daniels reported equity awards as part of his compensation. He received 3,990 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest in full on June 22, 2027, if he continues serving on the board until that date.

Daniels was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.92 per share, also vesting in full on June 22, 2027, subject to continued board service. Following the RSU grant, he directly holds 20,981 shares of BridgeBio common stock. The filing shows no open‑market buys or sells, only award-related acquisitions.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 2 txns

Insider DANIELS RONALD J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 20,981 shares (Direct)

Footnotes (3)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSU grant size: 3,990 RSUs Option grant size: 5,277 options Option exercise price: $68.92 per share +3 more

6 metrics

RSU grant size 3,990 RSUs Equity award to director on June 22, 2026

Option grant size 5,277 options Stock option covering common shares granted June 22, 2026

Option exercise price $68.92 per share Strike price for 5,277-share stock option

Option expiration June 21, 2036 Expiration date of stock option grant

Shares held after award 20,981 shares Director’s direct common stock holdings after RSU grant

Vesting date June 22, 2027 Full vesting date for RSUs and stock option, service-based

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, contingent right, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) ... transaction_shares": "5277.0000"..."

2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vesting financial

"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Pharma (BBIO) director Ronald J. Daniels receive in this Form 4?

Ronald J. Daniels received equity awards, not open-market trades. He was granted 3,990 restricted stock units and a stock option for 5,277 shares, both tied to continued service on BridgeBio’s board through June 22, 2027.

How many RSUs were granted to Ronald J. Daniels by BridgeBio Pharma?

Ronald J. Daniels was granted 3,990 restricted stock units. Each RSU represents a contingent right to receive one share of BridgeBio common stock, vesting in full on June 22, 2027 if he continues serving on the company’s board of directors.

What are the terms of Ronald J. Daniels’ new stock option in BridgeBio Pharma?

Daniels received a stock option for 5,277 shares of BridgeBio common stock at an exercise price of $68.92 per share. The option vests in full on June 22, 2027, conditioned on his continued service on the company’s board until that date.

Did Ronald J. Daniels buy or sell BridgeBio (BBIO) shares on the market in this filing?

The Form 4 reports no open-market purchases or sales. All transactions are coded as awards, reflecting grants of restricted stock units and stock options as compensation rather than discretionary buying or selling of BridgeBio common stock.

How many BridgeBio shares does Ronald J. Daniels hold after these awards?

After the RSU grant, Daniels directly holds 20,981 shares of BridgeBio common stock. This figure reflects his reported direct ownership following the non-cash equity award recorded on June 22, 2026 in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DANIELS RONALD J

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		A(1)		3,990	A	$0(2)	20,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		(3)	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)